RESUMEN
Cryptococcal meningitis accounts for 1 in 5 AIDS-related deaths globally. World Health Organization guidelines strongly recommend a single high dose of liposomal amphotericin B as part of preferred treatment, but this drug remains unaffordable in most low- and middle-income countries. A proactive approach is needed from manufacturers and other stakeholders to improve access.
Asunto(s)
Meningitis Criptocócica , Humanos , Meningitis Criptocócica/tratamiento farmacológico , Antifúngicos/uso terapéutico , Quimioterapia Combinada , Esquema de Medicación , Accesibilidad a los Servicios de Salud , Fluconazol/uso terapéuticoRESUMEN
Amphotericin B has long been crucial for treating many serious infectious diseases, such as invasive fungal infections and visceral leishmaniasis, particularly for patients who are immunocompromised, including those with advanced HIV infection. The conventional amphotericin B deoxycholate formulation has largely been replaced in high-income countries with liposomal amphotericin B (LAmB), which has many advantages, including lower rates of adverse events, such as nephrotoxicity and anaemia. Despite an evident need for LAmB in low-income and middle-income countries, where mortality from invasive fungal infections is still substantial, many low-income and middle-income countries still often use the amphotericin B deoxycholate formulation because of a small number of generic formulations and the high price of the originator LAmB. The pricing of LAmB is also highly variable between countries. Overcoming supply barriers through the availability of additional quality-assured, generic formulations of LAmB at accessible prices would substantially facilitate equitable access and have a substantial effect on mortality attributable to deadly fungal infections.
Asunto(s)
Anfotericina B , Antifúngicos , Humanos , Anfotericina B/economía , Antifúngicos/economía , Antifúngicos/provisión & distribución , Antifúngicos/uso terapéutico , Accesibilidad a los Servicios de Salud , Salud Global , Países en Desarrollo , Medicamentos Genéricos/economía , Medicamentos Genéricos/provisión & distribuciónRESUMEN
PURPOSE OF REVIEW: With increasing availability of generic direct-acting antivirals (DAAs) and associated price reductions, various governments, multilateral institutions, and donors have started providing testing and treatment for hepatitis C virus (HCV) infection. More data on the quality of these generic medicines and on cost-effectiveness of their use are becoming widely available. This review seeks to describe some of the treatment programs for HCV that are evolving in Cambodia, India, Indonesia, Malaysia, Myanmar, and Thailand. RECENT FINDINGS: The quality of multiple generic DAAs has been shown to be bioequivalent to innovator formulations, with generic versions achieving high cure rates in real-world settings. Although published materials are limited, there is expanding experience with local pilot and national treatment programs which are largely being funded by national governments and other institutions. SUMMARY: Countries and other public health stakeholders are recognizing the need to scale up HCV diagnosis and treatment programs using generic DAAs. However, local pilot or national treatment programs need to be massively expanded to eliminate HCV in high-burden areas.
Asunto(s)
Antivirales/uso terapéutico , Hepatitis C/diagnóstico , Hepatitis C/tratamiento farmacológico , Antivirales/economía , Asia , Análisis Costo-Beneficio , Medicamentos Genéricos/economía , Medicamentos Genéricos/uso terapéutico , Hepacivirus/genética , Hepacivirus/aislamiento & purificación , Hepacivirus/fisiología , Hepatitis C/economía , Hepatitis C/virología , HumanosRESUMEN
Viral hepatitis is a major public health threat and a leading cause of death worldwide. Annual mortality from viral hepatitis is similar to that of other major infectious diseases such as HIV and tuberculosis. Highly effective prevention measures and treatments have made the global elimination of viral hepatitis a realistic goal, endorsed by all WHO member states. Ambitious targets call for a global reduction in hepatitis-related mortality of 65% and a 90% reduction in new infections by 2030. This Commission draws together a wide range of expertise to appraise the current global situation and to identify priorities globally, regionally, and nationally needed to accelerate progress. We identify 20 heavily burdened countries that account for over 75% of the global burden of viral hepatitis. Key recommendations include a greater focus on national progress towards elimination with support given, if necessary, through innovative financing measures to ensure elimination programmes are fully funded by 2020. In addition to further measures to improve access to vaccination and treatment, greater attention needs to be paid to access to affordable, high-quality diagnostics if testing is to reach the levels needed to achieve elimination goals. Simplified, decentralised models of care removing requirements for specialised prescribing will be required to reach those in need, together with sustained efforts to tackle stigma and discrimination. We identify key examples of the progress that has already been made in many countries throughout the world, demonstrating that sustained and coordinated efforts can be successful in achieving the WHO elimination goals.
Asunto(s)
Gastroenterología/organización & administración , Salud Global/economía , Hepatitis/prevención & control , Hepatitis/virología , Adolescente , Adulto , Niño , Preescolar , Enfermedades Transmisibles/epidemiología , Enfermedades Transmisibles/mortalidad , Costo de Enfermedad , Atención a la Salud/métodos , Femenino , Salud Global/normas , Infecciones por VIH/mortalidad , Accesibilidad a los Servicios de Salud , Hepacivirus/aislamiento & purificación , Hepatitis/epidemiología , Hepatitis/mortalidad , Hepatitis B/epidemiología , Hepatitis B/mortalidad , Hepatitis B/prevención & control , Hepatitis B/transmisión , Virus de la Hepatitis B/aislamiento & purificación , Hepatitis C/epidemiología , Hepatitis C/mortalidad , Hepatitis C/prevención & control , Hepatitis C/transmisión , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Prevalencia , Tuberculosis/mortalidad , Vacunación/normas , Organización Mundial de la Salud , Adulto JovenRESUMEN
In 2018, WHO issued guidelines for the diagnosis, prevention, and management of HIV-related cryptococcal disease. Two strategies are recommended to reduce the high mortality associated with HIV-related cryptococcal meningitis in low-income and middle-income countries (LMICs): optimised combination therapies for confirmed meningitis cases and cryptococcal antigen screening programmes for ambulatory people living with HIV who access care. WHO's preferred therapy for the treatment of HIV-related cryptococcal meningitis in LMICs is 1 week of amphotericin B plus flucytosine, and the alternative therapy is 2 weeks of fluconazole plus flucytosine. In the ACTA trial, 1-week (short course) amphotericin B plus flucytosine resulted in a 10-week mortality of 24% (95% CI -16 to 32) and 2 weeks of fluconazole and flucytosine resulted in a 10-week mortality of 35% (95% CI -29 to 41). However, with widely used fluconazole monotherapy, mortality because of HIV-related cryptococcal meningitis is approximately 70% in many African LMIC settings. Therefore, the potential to transform the management of HIV-related cryptococcal meningitis in resource-limited settings is substantial. Sustainable access to essential medicines, including flucytosine and amphotericin B, in LMICs is paramount and the focus of this Personal View.